CBD’s Promise Outpaces Its Proof: A Comprehensive Review Finds Most Cannabis Products Lack Regulatory-Grade Evidence

Only Epidiolex for rare childhood epilepsies meets the gold standard for regulatory approval; the vast majority of CBD therapeutic uses remain unsupported by robust clinical trials, while product heterogeneity across the global market compounds safety and efficacy uncertainties for clinicians and patients alike.

Why This Matters

Cannabidiol has become one of the most widely discussed therapeutic compounds in modern medicine, yet the gap between consumer enthusiasm and clinical evidence continues to widen. Patients arrive in clinic already using CBD products for conditions ranging from chronic pain to anxiety, often assuming a level of scientific support that does not exist. This review arrives at a critical moment: global regulatory frameworks are expanding access to cannabis-derived products faster than the research infrastructure can evaluate them, making an honest accounting of what the evidence actually supports an urgent clinical and public health priority.

Clinical Summary

CBD occupies a unique pharmacological niche among cannabinoids. It lacks the psychotomimetic and abuse-reinforcing properties of THC while demonstrating a favorable tolerability profile across a broad dose range, which has made it attractive for therapeutic development. A 2024 narrative review published in Pharmaceuticals by Crippa, Zuardi, Hallak, Guimarães, and colleagues at the University of São Paulo’s Ribeirão Preto Medical School synthesizes the current evidence landscape for CBD and cannabis-derived products, drawing on five major databases. The review examines CBD’s pharmacology, the regulatory trajectory from Epidiolex to the broader commercial market, and the persistent challenges of product heterogeneity, manufacturing standards, and the often-cited but poorly defined “entourage effect” hypothesis.

The central finding is stark: only Epidiolex, a purified CBD formulation, has achieved regulatory-grade approval from both the FDA and EMA, and that approval is limited to three refractory childhood epilepsy syndromes: Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex. Sativex, a 1:1 THC:CBD product, holds approval for spasticity in multiple sclerosis in some jurisdictions, but evidence for most other cannabis-derived product indications remains preliminary or weak. The authors emphasize that the vast majority of commercially available CBD products do not meet Good Manufacturing Practice, Good Laboratory Practice, or Good Agricultural Practice standards, creating real quality and safety uncertainties. They conclude that rigorous, adequately powered randomized controlled trials are needed before clinical recommendations can responsibly extend beyond the narrow indications currently supported.

Dr. Caplan’s Take

This review articulates something I find myself explaining to patients regularly: the mechanistic promise of CBD is real, but the clinical evidence confirming that promise for most conditions simply is not there yet. Patients come to me having read persuasive testimonials or having already purchased products online, and they deserve an honest answer about where things stand. The authors are right that enthusiasm has outrun evidence, and that the product quality problem is not hypothetical. When you cannot be confident about what is actually in a product, you cannot be confident about its effects or its safety.

In practice, I discuss CBD with patients in the context of their full clinical picture, making clear distinctions between pharmaceutical-grade preparations and unregulated commercial products. For the rare epilepsy syndromes where Epidiolex has demonstrated efficacy, the conversation is evidence-based and straightforward. For everything else, I counsel patients about the uncertainty, monitor for drug interactions, particularly with medications metabolized through CYP3A4 and CYP2C19, and avoid recommending unregulated products for vulnerable populations including children and pregnant women. Transparency about the evidence gap is not discouraging; it is the foundation of trustworthy care.

Clinical Perspective

This review sits at the narrative synthesis stage of the research arc for CBD therapeutics, summarizing a field where a single approved indication has been rigorously validated while dozens of others remain in various stages of preliminary investigation. It confirms what prior systematic reviews and regulatory assessments have consistently shown: the evidence base for CBD outside of specific epilepsy syndromes is thin, fragmented, and frequently confounded by product variability. The entourage effect hypothesis, often invoked to justify full-spectrum or whole-plant extracts over purified CBD, is characterized here as too imprecise to guide either drug development or clinical decision-making. For clinicians, this means that patient-facing recommendations beyond the approved epilepsy indications cannot yet be grounded in high-quality evidence.

From a pharmacological standpoint, CBD’s interactions with cytochrome P450 enzymes, particularly CYP3A4 and CYP2C19, warrant careful attention in polypharmacy settings. Hepatotoxicity signals observed during Epidiolex trials, especially at higher doses or with concurrent valproate use, reinforce the importance of liver function monitoring. Unregulated products introduce additional risks from variable THC content, contaminants, and inaccurate labeling. The most actionable recommendation clinicians can implement now is to distinguish explicitly, in patient conversations and documentation, between pharmaceutical-grade CBD with regulatory approval and the wide spectrum of unregulated products, ensuring that any clinical use is monitored with the same rigor applied to any pharmacologically active compound.

Study at a Glance

Study Type

Narrative review

Population

Patients with epilepsy syndromes, multiple sclerosis, chronic pain, psychiatric conditions, and other indications; includes preclinical and clinical literature

Intervention

Cannabidiol (CBD) and cannabis-derived products (isolated, broad-spectrum, full-spectrum, synthetic)

Comparator

Pharmaceutical-grade CBD (Epidiolex) versus unregulated commercial cannabis products

Primary Outcomes

Efficacy, safety, regulatory status, and product quality across therapeutic indications

Sample Size

Not applicable (narrative review of selected literature)

Journal

Pharmaceuticals (MDPI, open access)

Year

2024

DOI

10.3390/ph17121644

Funding Source

Not reported in extracted text

What Kind of Evidence Is This

This is an expert-authored narrative review published in an open-access journal. Narrative reviews sit below systematic reviews and meta-analyses in the evidence hierarchy because they do not follow pre-registered search protocols, do not apply standardized quality appraisal to included studies, and cannot generate pooled effect estimates. The single most important inference constraint this imposes is that the conclusions, however well-reasoned, reflect the authors’ selective synthesis of available literature rather than a reproducible, comprehensive assessment of all relevant evidence.

How This Fits With the Broader Literature

This review aligns closely with prior assessments, including the 2018 National Academies of Sciences report on cannabis therapeutics and the Cochrane reviews on cannabinoids for epilepsy, which consistently find strong evidence limited to a narrow set of indications and significant uncertainty elsewhere. It extends prior work by foregrounding the product quality problem as a distinct and compounding barrier to evidence generation, an issue that has grown more pressing as the commercial market has expanded globally. The authors’ skepticism toward the entourage effect echoes critiques published by Cather and colleagues and by Russo’s own acknowledgment that the concept requires far more rigorous pharmacological definition before it can meaningfully inform clinical practice or product regulation.

Common Misreadings

The most likely overinterpretation of this review is to conclude that CBD has been shown to be ineffective for conditions beyond epilepsy. That is not what the evidence shows. The review’s actual conclusion is that the evidence is insufficient, not that negative evidence exists. Absence of adequate clinical trials is a statement about the research landscape, not about the compound’s pharmacological potential. A second common misreading runs in the opposite direction: assuming that because CBD is well-tolerated and has regulatory approval for epilepsy, it is therefore safe and effective for any condition at any dose in any formulation. The review explicitly warns against this extrapolation, particularly for unregulated products.

Bottom Line

This narrative review provides a valuable, expert-level synthesis confirming that regulatory-grade evidence for CBD-based therapeutics remains confined to specific refractory epilepsy syndromes. It does not establish that CBD is ineffective for other conditions; it establishes that we do not yet know with adequate rigor. For clinicians, the practical implication is clear: distinguish between pharmaceutical-grade and unregulated products, monitor as you would any pharmacologically active agent, and communicate the evidence gap to patients with honesty and precision.

References

1. Crippa JA, Zuardi AW, Hallak JEC, Guimarães FS, et al. Therapeutic and pharmaceutical development of cannabinoid-based medicines. Pharmaceuticals. 2024;17(12):1644. DOI: 10.3390/ph17121644
2. National Academies of Sciences, Engineering, and Medicine. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington, DC: The National Academies Press; 2017. DOI: 10.17226/24625
3. Stockings E, Zagic D, Campbell G, et al. Evidence for cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational evidence. J Neurol Neurosurg Psychiatry. 2018;89(7):741-753. DOI: 10.1136/jnnp-2017-317168
4. Devinsky O, Cross JH, Laux L, et al. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med. 2017;376(21):2011-2020. DOI: 10.1056/NEJMoa1611618
5. Thiele EA, Marsh ED, French JA, et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391(10125):1085-1096. DOI: 10.1016/S0140-6736(18)30136-3